Home
About + Prices
Contact Us
News Team
Social Media
Distribution
References
Archive
Share this story:
Anteris Technologies hails FDA early feasibility study approval for DurAVR™
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com